Update on biomarkers in neuromyelitis optica

Esther Melamed, Michael Levy, Patrick J. Waters, Douglas Kazutoshi Sato, Jeffrey L. Bennett, Gareth R. John, Douglas C. Hooper, Albert Saiz, Amit Bar-Or, Ho Jin Kim, Lakha Pandit, Maria Isabel Leite, Nasrin Asgari, Najib Kissani, Rogier Hintzen, Romain Marignier, Sven Jarius, John Marcelletti, Terry J. Smith, Michael R. Yeaman & 1 others May H. Han

Research output: Contribution to journalReview article

Abstract

Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.

Original languageEnglish (US)
Article numbere134
JournalNeurology: Neuroimmunology and NeuroInflammation
Volume2
Issue number4
DOIs
StatePublished - 2015

Fingerprint

Neuromyelitis Optica
Biomarkers
Aquaporin 4
Immunoglobulin G
Recurrence
Spinal Nerves
Optic Nerve
Nervous System
Autoimmune Diseases
Spinal Cord
Therapeutics
Clinical Trials
Antibodies
Serum

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Melamed, E., Levy, M., Waters, P. J., Sato, D. K., Bennett, J. L., John, G. R., ... Han, M. H. (2015). Update on biomarkers in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2(4), [e134]. https://doi.org/10.1212/NXI.0000000000000134

Update on biomarkers in neuromyelitis optica. / Melamed, Esther; Levy, Michael; Waters, Patrick J.; Sato, Douglas Kazutoshi; Bennett, Jeffrey L.; John, Gareth R.; Hooper, Douglas C.; Saiz, Albert; Bar-Or, Amit; Kim, Ho Jin; Pandit, Lakha; Leite, Maria Isabel; Asgari, Nasrin; Kissani, Najib; Hintzen, Rogier; Marignier, Romain; Jarius, Sven; Marcelletti, John; Smith, Terry J.; Yeaman, Michael R.; Han, May H.

In: Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, No. 4, e134, 2015.

Research output: Contribution to journalReview article

Melamed, E, Levy, M, Waters, PJ, Sato, DK, Bennett, JL, John, GR, Hooper, DC, Saiz, A, Bar-Or, A, Kim, HJ, Pandit, L, Leite, MI, Asgari, N, Kissani, N, Hintzen, R, Marignier, R, Jarius, S, Marcelletti, J, Smith, TJ, Yeaman, MR & Han, MH 2015, 'Update on biomarkers in neuromyelitis optica', Neurology: Neuroimmunology and NeuroInflammation, vol. 2, no. 4, e134. https://doi.org/10.1212/NXI.0000000000000134
Melamed, Esther ; Levy, Michael ; Waters, Patrick J. ; Sato, Douglas Kazutoshi ; Bennett, Jeffrey L. ; John, Gareth R. ; Hooper, Douglas C. ; Saiz, Albert ; Bar-Or, Amit ; Kim, Ho Jin ; Pandit, Lakha ; Leite, Maria Isabel ; Asgari, Nasrin ; Kissani, Najib ; Hintzen, Rogier ; Marignier, Romain ; Jarius, Sven ; Marcelletti, John ; Smith, Terry J. ; Yeaman, Michael R. ; Han, May H. / Update on biomarkers in neuromyelitis optica. In: Neurology: Neuroimmunology and NeuroInflammation. 2015 ; Vol. 2, No. 4.
@article{05abe6892efa4145899888580bac6fa5,
title = "Update on biomarkers in neuromyelitis optica",
abstract = "Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.",
author = "Esther Melamed and Michael Levy and Waters, {Patrick J.} and Sato, {Douglas Kazutoshi} and Bennett, {Jeffrey L.} and John, {Gareth R.} and Hooper, {Douglas C.} and Albert Saiz and Amit Bar-Or and Kim, {Ho Jin} and Lakha Pandit and Leite, {Maria Isabel} and Nasrin Asgari and Najib Kissani and Rogier Hintzen and Romain Marignier and Sven Jarius and John Marcelletti and Smith, {Terry J.} and Yeaman, {Michael R.} and Han, {May H.}",
year = "2015",
doi = "10.1212/NXI.0000000000000134",
language = "English (US)",
volume = "2",
journal = "Neurology: Neuroimmunology and NeuroInflammation",
issn = "2332-7812",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "4",

}

TY - JOUR

T1 - Update on biomarkers in neuromyelitis optica

AU - Melamed, Esther

AU - Levy, Michael

AU - Waters, Patrick J.

AU - Sato, Douglas Kazutoshi

AU - Bennett, Jeffrey L.

AU - John, Gareth R.

AU - Hooper, Douglas C.

AU - Saiz, Albert

AU - Bar-Or, Amit

AU - Kim, Ho Jin

AU - Pandit, Lakha

AU - Leite, Maria Isabel

AU - Asgari, Nasrin

AU - Kissani, Najib

AU - Hintzen, Rogier

AU - Marignier, Romain

AU - Jarius, Sven

AU - Marcelletti, John

AU - Smith, Terry J.

AU - Yeaman, Michael R.

AU - Han, May H.

PY - 2015

Y1 - 2015

N2 - Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.

AB - Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.

UR - http://www.scopus.com/inward/record.url?scp=84969320801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969320801&partnerID=8YFLogxK

U2 - 10.1212/NXI.0000000000000134

DO - 10.1212/NXI.0000000000000134

M3 - Review article

VL - 2

JO - Neurology: Neuroimmunology and NeuroInflammation

JF - Neurology: Neuroimmunology and NeuroInflammation

SN - 2332-7812

IS - 4

M1 - e134

ER -